Veru reports fiscal 2024 second quarter financial results and progress of its enobosarm high quality weight loss clinical program

--phase 2b clinical study of enobosarm in combination with semaglutide (wegovy ® * ) for high quality weight loss is actively enrolling-- --company assembles esteemed high quality weight loss scientific advisory board – five mds with significant relevant medical, clinical and scientific expertise--
VERU Ratings Summary
VERU Quant Ranking